Скачать или смотреть “$CSTL Breakout? | Castle Biosciences Stock Update 2025 🚀”

Latest update on Castle Biosciences ($CSTL):

Q2 2025 revenue: $86.2 million, up 6% in test volumes

Full-year 2025 guidance raised to $310–320 million

Growth driven by DecisionDx-Melanoma & TissueCypher, despite IDgenetix discontinuation

Analysts stay bullish with an average target of $37.67 (~65% upside)

Technical forecast shows short-term range near $23.10

Would you bet on CSTL’s next breakout or stay cautious? Comment below!

#CSTL #CastleBiosciences #Biotech #HealthcareStocks #StockMarket #Investing #Shorts #NASDAQ #StockUpdate #Diagnostics
Search Queries

CSTL stock news today
Castle Biosciences Q2 2025 results
CSTL analyst price target
Is CSTL stock a buy
DecisionDx Melanoma test
TissueCypher updates
CSTL stock forecast 2025
Castle Biosciences news update


⚠️ Disclaimer: For educational purposes only. Not financial advice.